Skip to main content
رجوع
ANRO logo

Alto Neuroscience, Inc.

جودة البيانات: 100%
ANRO
NYSE Healthcare Biotechnology
KWD 20.67
▲ KWD 0.48 (2.38%)
القيمة السوقية: 660.31M
نطاق اليوم
KWD 19.98 KWD 21.12
نطاق 52 أسبوعًا
KWD 1.60 KWD 25.17
حجم التداول
186,074
متوسط 50 يوم / 200 يوم
KWD 18.43 / KWD 10.24
الإغلاق السابق
KWD 20.19

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E -10.4 0.2
P/B 4.4 3.0
ROE % -41.8 3.6
Net Margin % 3.8
Rev Growth 5Y % 9.7
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 26.33 +27.4%
Low: KWD 16.00 High: KWD 35.00
ربحية السهم المستقبلية
-KWD 2.41
الإيرادات المقدّرة
0.0

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 1.09
KWD 1.09 – KWD 1.09
294.45M 2
FY2029 -KWD 2.41
-KWD 2.41 – -KWD 2.41
49.02M 4
FY2028 -KWD 2.88
-KWD 4.11 – -KWD 2.15
9.30M 6

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-16 -KWD 0.53 -KWD 0.45 +15.3%
2025-11-12 -KWD 0.66 -KWD 0.52 +21.2%
2025-08-13 -KWD 0.57 -KWD 0.65 -14.0%
2025-05-14 -KWD 0.59 -KWD 0.53 +10.2%
2025-03-20 -KWD 0.65 -KWD 0.56 +13.8%
2024-11-12 -KWD 0.67 -KWD 0.62 +7.5%
2024-08-13 -KWD 0.71 -KWD 0.60 +15.5%
2024-05-14 -KWD 0.46 -KWD 0.76 -65.2%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Debt/Equity of 0.03 — conservative balance sheet
Negative free cash flow of -51.79M
PEG of 0.65 suggests growth is underpriced

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-41.80%
ROIC-32.00%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
0.03
Current Ratio15.69
Interest Coverage-26.88

التقييم

P/E Ratio
-10.44
Forward P/EN/A
P/B Ratio4.37
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -63.24M
ROE -41.80% ROA -34.24%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -51.79M
ROIC -32.00% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.03 Current Ratio 15.69
Interest Coverage -26.88
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10.44 Forward P/E N/A
P/B Ratio 4.37 P/S Ratio N/A
PEG Ratio 0.65 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7.84%
Market Cap 660.31M Enterprise Value 488.24M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 210,000.0
Net Income -63.24M -61.43M -36.31M -27.71M -9.19M
EPS (Diluted) -2.19 -2.50 -1.35 -1.08 -0.36
Gross Profit -661,000.0 -502,000.0 0.0 -342,000.0 65,000.0
Operating Income -66.36M -68.61M -37.81M -29.19M -12.06M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 184.69M 177.54M 86.63M 50.85M 28.79M
Total Liabilities 33.55M 26.08M 158.30M 89.26M 41.27M
Shareholders' Equity 151.14M 151.46M -71.67M -38.41M -12.48M
Total Debt 4.41M 16.94M 9.99M 82.11M 38.16M
Cash & Equivalents 176.48M 168.23M 82.55M 48.34M 25.71M
Current Assets 177.72M 169.34M 85.39M 49.22M 27.68M
Current Liabilities 11.33M 10.01M 5.61M 5.56M 1.81M